Daiichi Sankyo announces commencement of clinical trials in Japan for Duchenne muscular dystrophy treatment

Daiichi SankyoDaiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced today that administration of the Duchenne muscular dystrophy (hereafter, DMD) treatment drug DS-5141b (hereafter, the Drug), which is jointly developing with the Orphan Disease Treatment Institute Co., Ltd. (hereafter, ODTI), to the first subject has begun in the first clinical trial in Japan.

DMD is known as a disease that affects one in 3,500 new-born males regardless of ethnicity. It is known that DMD occurs because muscle cells do not produce dystrophin, but there is no fundamental therapy available.

Because the Drug induces exon 45 skipping of a dystrophin mRNA to promote incomplete but functional dystrophin production, it is expected to be an effective treatment for DMD. The Drug contains the active ingredient ENA® oligonucleotide, a modified nucleic acid made using proprietary technology owned by Daiichi Sankyo. Daiichi Sankyo expects to obtain manufacturing and marketing approval by the end of 2020.

Daiichi Sankyo remains committed to meeting the needs of more patients and medical professionals through drug development and contributing to medical care by providing new treatment options.

About ODTI
Daiichi Sankyo jointly established the ODTI with the Innovation Network Corporation of Japan and a fund managed by Mitsubishi UFJ Capital Co., Ltd. - see Daiichi Sankyo press release dated February 14, 2013 entitled, Daiichi Sankyo Announces Development of Nucleic Acid Treatment for Duchenne Muscular Dystrophy Utilizing Proprietary Technology.

About ENA® oligonucleotides
ENA® is an ethylene-bridged nucleic acid in which ethylene is bridged at the furanose sugar ring at 2'-O and 4'-C ends. Short-chain nucleic acids and ENA® oligonucleotides found in ENA® demonstrate high binding force with complementary DNA and RNA as well as superior thermal stability and nuclease resistance. ENA® is a registered trademark of Daiichi Sankyo.

About Daiichi Sankyo
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address diversified, unmet medical needs of patients in both mature and emerging markets. With over 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 17,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to its strong portfolio of medicines for hypertension, dyslipidemia, bacterial infections, and thrombotic disorders, the Group’s research and development is focused on bringing forth novel therapies in cardiovascular-metabolic diseases, pain management, and oncology, including biologics.

Most Popular Now

Amgen announces Repatha® (evolocumab) significantl…

Amgen (NASDAQ:AMGN) has announced that the FOURIER trial evaluating whether Repatha® (evolocumab) reduces the risk of cardiovascular events in patients with clinically ev...

Read more

Too much sitting, too little exercise may accelera…

Researchers at University of California San Diego School of Medicine report that elderly women who sit for more than 10 hours a day with low physical activity have cells ...

Read more

Lilly and CoLucid Pharmaceuticals announce agreeme…

Eli Lilly and Company (NYSE: LLY) and CoLucid Pharmaceuticals, Inc. (NASD: CLCD) have announced an agreement for Lilly to acquire CoLucid for $46.50 per share or approxim...

Read more

Vitamin D discovery could prove key to new treatme…

A team led by Motonari Uesugi, professor and deputy director of Kyoto University's Institute for Integrated Cell-Material Sciences (iCeMS), found that a vitamin D metabol...

Read more

Structure of atypical cancer protein paves way for…

A team of researchers from Case Western Reserve University School of Medicine has helped uncover the elusive structure of a cancer cell receptor protein that can be lever...

Read more

Merck announces research collaboration with Domain…

Merck, a leading science and technology company, today announced it has entered into a collaboration and licensing agreement with Domain Therapeutics, Strasbourg, France...

Read more

AstraZeneca expands 1st-line lung cancer Immuno-On…

AstraZeneca has provided an update on its Immuno-Oncology (IO) late-stage clinical development programme in 1st-line non-small cell lung cancer (NSCLC), including a refin...

Read more

The drugs don't work, say back pain researchers

Commonly used non-steroidal anti-inflammatory drugs, such as ibuprofen, used to treat back pain provide little benefit, but cause side effects, according to new research ...

Read more

Nuts can inhibit the growth of cancer cells

Roasted and salted, ground as a baking ingredient or fresh from the shell - for all those who enjoy eating nuts, there is good news from nutritionists at Friedrich Schill...

Read more

Novo Nordisk enters collaboration with University …

University of Oxford and Novo Nordisk today announced a landmark research collaboration focused on type 2 diabetes. The partnership will enable scientists from Novo Nordi...

Read more

Pfizer reports fourth-quarter and full-year 2016 r…

Pfizer Inc. (NYSE: PFE) reported financial results for fourth-quarter and full-year 2016 and provided 2017 financial guidance. Pfizer manages its commercial operations th...

Read more

Anti-inflammatory diet could reduce risk of bone l…

Anti-inflammatory diets - which tend to be high in vegetables, fruits, fish and whole grains - could boost bone health and prevent fractures in some women, a new study su...

Read more

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]